1.Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction.
Doo Sun SIM ; Myung Ho JEONG ; Ho Chun SONG ; Jahae KIM ; Ari CHONG ; Hee Seung BOM ; In Seok JEONG ; Sang Gi OH ; Jong Min KIM ; Dae Sung PARK ; Jung Ha KIM ; Kyung Seob LIM ; Min Suk KIM ; Shi Hyun RYU ; Hyun Kuk KIM ; Sung Soo KIM ; Su Young JANG ; Jae Yeong CHO ; Hae Chang JEONG ; Ki Hong LEE ; Keun Ho PARK ; Nam Sik YOON ; Hyun Ju YOON ; Kye Hun KIM ; Young Joon HONG ; Hyung Wook PARK ; Ju Han KIM ; Youngkeun AHN ; Jeong Gwan CHO ; Jong Chun PARK ; Jung Chaee KANG
Journal of Korean Medical Science 2015;30(1):34-43
Cardioprotective effect of fimasartan, a new angiotensin receptor blocker (ARB), was evaluated in a porcine model of acute myocardial infarction (MI). Fifty swine were randomized to group 1 (sham, n=10), group 2 (no angiotensin-converting enzyme inhibitor [ACEI] or ARB, n=10), group 3 (perindopril 2 mg daily, n=10), group 4 (valsartan 40 mg daily, n=10), or group 5 (fimasartan 30 mg daily, n=10). Acute MI was induced by occlusion of the left anterior descending artery for 50 min. Echocardiography, single photon emission computed tomography (SPECT), and F-18 fluorodeoxyglucose cardiac positron emission tomography (PET) were performed at baseline, 1 week, and 4 weeks. Iodine-123 meta-iodobenzylguanidine (MIBG) scan was done at 6 weeks for visualization of cardiac sympathetic activity. Left ventricular function and volumes at 4 weeks were similar between the 5 groups. No difference was observed in groups 2 to 5 in SPECT perfusion defect, matched and mismatched segments between SPECT and PET at 1 week and 4 weeks. MIBG scan showed similar uptake between the 5 groups. Pathologic analysis showed similar infarct size in groups 2 to 5. Infarct size reduction was not observed with use of fimasartan as well as other ACEI and ARB in a porcine model of acute MI.
3-Iodobenzylguanidine
;
Angiotensin II Type 1 Receptor Blockers/therapeutic use
;
Angiotensin Receptor Antagonists/*therapeutic use
;
Angiotensin-Converting Enzyme Inhibitors/therapeutic use
;
Animals
;
Anterior Wall Myocardial Infarction/*drug therapy/physiopathology
;
Biphenyl Compounds/*therapeutic use
;
Cardiotonic Agents/*therapeutic use
;
Disease Models, Animal
;
Echocardiography
;
Fluorodeoxyglucose F18
;
Perindopril/therapeutic use
;
Positron-Emission Tomography
;
Pyrimidines/*therapeutic use
;
Random Allocation
;
Swine
;
Tetrazoles/*therapeutic use
;
Tomography, Emission-Computed, Single-Photon
;
Valsartan/therapeutic use
;
Ventricular Function, Left/*physiology
Result Analysis
Print
Save
E-mail